<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">Since the novel coronavirus belongs to the same category of SARS, repurposing of HIV drugs against novel coronavirus could give positive efficacy. Lopinavir may have some prospects in COVID-19 therapy as has been in the SARS and MERS treatment; however, an extensive evaluation is required [
 <xref ref-type="bibr" rid="CR174">174</xref>]. Efficacy of remdesivir against SARS-CoV-2 is under testing by Gilead Sciences (NASDAQ-GILD) pharmaceutical company (
 <ext-link ext-link-type="uri" xlink:href="https://www.fool.com/investing/2020/03/04/is-gilead-sciences-the-best-buy-in-the-coronavirus.aspx" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fool.com/investing/2020/03/04/is-gilead-sciences-the-best-buy-in-the-coronavirus.aspx</ext-link>). National Health Commission of the Peopleâ€™s Republic of China has advocated the inclusion of chloroquine phosphate for the cure of COVID-19 patients, in its revised guidelines for the prevention, diagnosis, and treatment of pneumonia developed due to COVID-19 infection in the vast populous country [
 <xref ref-type="bibr" rid="CR175">175</xref>, 
 <xref ref-type="bibr" rid="CR176">176</xref>]. Future research could continue to screen currently clinically available small molecular antiviral drugs in tissue culture models to identify candidate drugs to combat the novel coronavirus infection.
</p>
